mash and glp 1 Incretin-based therapies in MASLD/MASH: from GLP-1 receptor agonists to dual triple agonists Novo Nordisk leads MASH therapeutic

Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes

In saline-treated rats, early myocardial damage appeared by day 24, marked by a significant increase in left ventricular systolic diameter

Theyre fascinating drugs for which scientists have already found many good uses, Standaert says, but that doesnt mean they cure everything. At this point, he says, I think we need to back up a little bit and ask ourselves, How do these GLP-1s work anyway? Sperling echoes the thought

The SURMOUNT-1 trial for tirzepatide capped doses at 15 mg weekly with 20.9% mean body-weight reduction (Jastreboff et al., 2022)

Why Scar Age Matters Clinical research reveals an important finding: scar age affects treatment response

Recovery and downtime are significantly less as well